vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

/PRNewswire/ -- vasopharm GmbH ("vasopharm"), a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular diseases,...

Related Keywords

Germany ,Glasgow ,Glasgow City ,United Kingdom ,Nostra ,Käten ,Austria ,Switzerland ,France ,Spain ,Harald Schmidt ,John Stover ,Ulrich Walter ,Erich Schmutzhard ,University Of Innsbruck ,Drug Monitoring Committee ,Clinical Development Plan For Ronopterin ,Clinical Development Plan ,Medical University ,Chief Investigator ,Glasgow Outcome Scale ,Unfavorable Outcome ,Favorable Outcome ,Good Recovery ,Intensity Level ,Chief Medical Officer ,Traumatic Brain Injury ,Medical School ,Clinical Biochemistry ,Nitric Oxide Synthase ,Glasgow Outcome Score ,Full Analysis Set ,Glasgow Outcomes Scale ,Vasopharm ,